Literature DB >> 10096937

Electrocardiographic signs of chronic cor pulmonale: A negative prognostic finding in chronic obstructive pulmonary disease.

R A Incalzi1, L Fuso, M De Rosa, A Di Napoli, S Basso, G Pagliari, R Pistelli.   

Abstract

BACKGROUND: Chronic cor pulmonale (CCP) is a strong predictor of death in chronic obstructive pulmonary disease (COPD). The aims of this study were to assess the prognostic role of individual ECG signs of CCP and of the interaction between these signs and abnormal arterial blood gases. METHODS AND
RESULTS: Two hundred sixty-three patients (217 men) with COPD, mean age 67+/-9 years, were grouped according to whether they had no ECG signs (group 1, n=100) or >/=1 ECG signs (group 2, n=163) of CCP and were followed up for 13 years after an exacerbation of respiratory failure. The median survival was significantly shorter in group 2 than in group 1 (2.58 versus 3. 45 years, respectively; Mantel-Cox test, 9.58; P=0.002). The Cox regression analysis identified S1S2S3 pattern, right atrial overload (RAO), and alveolar-arterial oxygen gradient (PAO2-PaO2) >48 mm Hg during oxygen therapy as the strongest predictors of death, with hazard rate (HR)=1.81 (95% CI, 1.22 to 2.69), HR=1.58 (95% CI, 1.15 to 2.18), and HR=1.96 (95% CI, 1.19 to 3.25), respectively. The median survivals of patients having both S1S2S3 pattern and RAO (n=14) and of patients having either S1S2S3 pattern or RAO (n=77) were 1.33 and 2.70 years, respectively (P=0.022). Group 2 patients had a 3-year survival of 18% or 53%, depending on whether their PAO2-PaO2 during oxygen therapy was or was not >48 mm Hg.
CONCLUSIONS: Some ECG signs of CCP and PAO2-PaO2 >48 mm Hg during oxygen therapy qualified as a simple and inexpensive tool for targeting subsets of COPD patients with severe or very severe short-term prognosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10096937     DOI: 10.1161/01.cir.99.12.1600

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  22 in total

Review 1.  Pulmonary hypertension in chronic obstructive pulmonary disease and emphysema patients: prevalence, therapeutic options and pulmonary circulatory effects of lung volume reduction surgery.

Authors:  Isabelle Opitz; Silvia Ulrich
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

2.  Computed tomographic measures of pulmonary vascular morphology in smokers and their clinical implications.

Authors:  Raúl San José Estépar; Gregory L Kinney; Jennifer L Black-Shinn; Russell P Bowler; Gordon L Kindlmann; James C Ross; Ron Kikinis; Meilan K Han; Carolyn E Come; Alejandro A Diaz; Michael H Cho; Craig P Hersh; Joyce D Schroeder; John J Reilly; David A Lynch; James D Crapo; J Michael Wells; Mark T Dransfield; John E Hokanson; George R Washko
Journal:  Am J Respir Crit Care Med       Date:  2013-07-15       Impact factor: 21.405

3.  Electrocardiographic differences between COPD patients evaluated for lung transplantation with and without pulmonary hypertension.

Authors:  Laith Alkukhun; Manfred Baumgartner; Marie Budev; Raed A Dweik; Adriano R Tonelli
Journal:  COPD       Date:  2014-07-01       Impact factor: 2.409

4.  Effects of the association of diabetes and pulmonary emphysema on cardiac structure and function in rats.

Authors:  Antonio Di Petta; Rafael Simas; Clebson L Ferreira; Vera L Capelozzi; Vera M C Salemi; Luiz F P Moreira; Paulina Sannomiya
Journal:  Int J Exp Pathol       Date:  2015-10-29       Impact factor: 1.925

5.  mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia.

Authors:  Vera P Krymskaya; Jennifer Snow; Gregory Cesarone; Irene Khavin; Dmitry A Goncharov; Poay N Lim; Sigrid C Veasey; Kaori Ihida-Stansbury; Peter L Jones; Elena A Goncharova
Journal:  FASEB J       Date:  2011-03-02       Impact factor: 5.191

Review 6.  The structural basis of pulmonary hypertension in chronic lung disease: remodelling, rarefaction or angiogenesis?

Authors:  Natalie Hopkins; Paul McLoughlin
Journal:  J Anat       Date:  2002-10       Impact factor: 2.610

Review 7.  Cardiac disease in chronic obstructive pulmonary disease.

Authors:  Jeremy A Falk; Steven Kadiev; Gerard J Criner; Steven M Scharf; Omar A Minai; Philip Diaz
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

8.  JNK2 up-regulates hypoxia-inducible factors and contributes to hypoxia-induced erythropoiesis and pulmonary hypertension.

Authors:  Marc A Sala; Cong Chen; Qiao Zhang; Hanh Chi Do-Umehara; Wenjiao Wu; Alexander V Misharin; Gregory B Waypa; Deyu Fang; G R Scott Budinger; Shuwen Liu; Navdeep S Chandel; Paul T Schumacker; Jacob I Sznajder; Jing Liu
Journal:  J Biol Chem       Date:  2017-11-08       Impact factor: 5.157

Review 9.  Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management.

Authors:  Joan Albert Barberà; Isabel Blanco
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

Review 10.  Pulmonary hypertension and chronic cor pulmonale in COPD.

Authors:  Adil Shujaat; Ruth Minkin; Edward Eden
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.